VUMC ACEi cough implementation |
ACE Inhibitor (ACE-I) induced cough |
Vanderbilt University |
Case, Control |
|
|
100%, 100% |
96% |
Vanderbilt implementation |
Clostridium Difficile Colitis |
|
Case, Control |
|
|
100%, 100% |
|
Validation of ACEi-induced cough algorithm |
ACE Inhibitor (ACE-I) induced cough |
Mayo Clinic |
Case, Control |
|
|
100%, 96% |
|
Marshfield Hearing loss validation |
Hearing Loss |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
25 |
100%, 100% |
|
Marshfield C-diff implementation |
Clostridium Difficile Colitis |
Marshfield Clinic Research Foundation |
Case, Control |
21 |
10 |
100%, 100% |
|
Marshfield implementation |
CAAD (Carotid Artery Atherosclerosis Disease) |
Marshfield Clinic Research Foundation |
Case, Control |
71 |
435 |
100%, 100% |
100% |
NU ACE Inhibitor (ACE-I) induced cough implementation |
ACE Inhibitor (ACE-I) induced cough |
Northwestern University The Feinberg School of Medicine |
Case, Control |
|
|
100%, 98% |
|
Marshfield AAA implementation |
Abdominal Aortic Aneurysm ( AAA ) |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
22 |
100%, 100% |
|
Mayo FH Implementation |
Electronic Health Record-based Phenotyping Algorithm for Familial Hypercholesterolemia |
Mayo Clinic |
Case, Control |
58 |
42 |
100%, 98% |
100%, 100% |
caMRSA chart verification |
caMRSA |
GHRI/UW |
Case, Control |
72 |
2,310 |
100%, 100% |
100%, 100% |
Marshfield ACE-I cough implentation |
ACE Inhibitor (ACE-I) induced cough |
Marshfield Clinic Research Foundation |
Case, Control |
25 |
25 |
100%, 96% |
|
GH/UW Verification |
Gastroesophageal Reflux Disease (GERD) Phenotype Algorithm |
Group Health and University of Washington |
Case, Control |
479 |
319 |
100%, 100% |
100%, 100% |
Implementation For Phase 3 eMERGE |
Electronic Health Record-based Phenotyping Algorithm for Familial Hypercholesterolemia |
Geisinger |
Case, Control |
25 |
25 |
100%, 96% |
|
Marshfield implementation |
caMRSA |
Marshfield Clinic Research Foundation |
Case, Control |
|
|
100%, 100% |
100%, 100% |
Geisinger c.Diff eMERGE3 Implementation |
Clostridium Difficile Colitis |
Geisinger |
Case, Control |
20 |
20 |
100%, 100% |
100%, 100% |
Marshfield Implementation 2 |
CAAD (Carotid Artery Atherosclerosis Disease) |
Marshfield Clinic Research Foundation |
Case, Control |
193 |
4,170 |
100%, 100% |
|
Geisinger Impl |
Colorectal Cancer (CRC) |
Geisinger |
Case, Control |
25 |
25 |
100%, 100% |
|
Mayo Clinic CAAD Evaluation |
CAAD (Carotid Artery Atherosclerosis Disease) |
Mayo Clinic |
Case, Control |
|
|
100% |
72% |
CHOP NAFLD |
Non-alcoholic fatty liver disease (NALFD) & Alcoholic Fatty Liver Disease (ALD) |
CHOP |
Case Only |
12 |
|
100% |
|
Cardiac Conduction Marshfield Implementation |
Cardiac Conduction (QRS) |
Marshfield Clinic Research Foundation |
Case Only |
|
|
100% |
|
NU appendicitis cases |
Appendicitis |
Northwestern University |
Case Only |
30 |
|
100% |
|
Mayo CAAD cases and controls |
CAAD (Carotid Artery Atherosclerosis Disease) |
Mayo |
Case, Control |
13 |
|
100% |
71% |
Group Health and UW Zoster Implementation |
Herpes Zoster |
Group Health and UW |
Case, Control |
25 |
25 |
100%, 96% |
100% |